NEOADJUVANT THERAPY

This study tests a drug called Vebreltinib given for 8 weeks before surgery in people with a specific type of lung cancer (stage IIA-IIIB NSCLC with a MET gene change). The goal is to see if the drug can shrink tumors enough to improve surgery outcomes. About 30 participants will…

This study tests a new approach for women with a common type of early breast cancer (HR+/HER2-). Instead of standard chemotherapy before surgery, some participants will receive a targeted drug (abemaciclib) plus hormone therapy, based on a gene test result. The goal is to see if …

This pilot study looks at whether it is safe and feasible to skip surgery in patients with stage II-III non-small cell lung cancer who have a complete response to chemotherapy and immunotherapy. Fourteen participants will be randomly assigned to either observation or standard sur…

This study tests an oral chemotherapy drug (paclitaxel) combined with immunotherapy given before surgery for elderly patients (ages 70-85) with non-small cell lung cancer. The goal is to see if this approach can shrink tumors and improve outcomes. About 75 participants will recei…

This study tests a combination of two drugs (zanidatamab and tislelizumab) plus chemotherapy or radiation in people with HER2-positive gastrointestinal cancers, including rectal, stomach, and colorectal cancers. The goal is to see if this treatment can shrink tumors before surger…

This study tests a new approach for people with early-stage triple-negative breast cancer. It combines an immunotherapy drug (QL1706) with chemotherapy before surgery. The key idea is to use scans and biopsies after the first part of treatment to see who responds well. Those who …

This study tests whether giving a combination of three drugs (camrelizumab, chemotherapy, and ivarmacitinib) before surgery can improve outcomes for people with a type of esophageal cancer. About 45 adults with stage II to IVA esophageal squamous cell carcinoma will receive this …

This study tests whether adding the drug adebrelimab to standard chemotherapy before surgery can help remove pancreatic cancer more completely. About 30 adults with resectable pancreatic cancer will receive the combination treatment. The goal is to see if this approach improves t…

This study tests if a family-supervised program combining exercise, nutrition advice, and psychological support can reduce serious complications after stomach cancer surgery. About 90 adults who will receive chemotherapy before surgery will be randomly assigned to either the prog…

This study tests whether combining two drugs (sacituzumab tirumotecan and pembrolizumab) before surgery can eliminate all signs of cancer in people with stage II or III triple-negative breast cancer. About 52 participants who have not had prior treatment will receive the drugs fo…

This study tests whether adding the experimental drug Ivonescimab to standard chemotherapy before surgery can improve outcomes for people with resectable esophageal squamous cell carcinoma. About 49 adults with stage II to IVA cancer will receive the combination, then have surger…

This study tests a simple idea: wearing tight surgical gloves during chemotherapy sessions might prevent nerve damage in the hands. About 44 breast cancer patients will try it on one hand only, so doctors can compare. The goal is to see if this cheap, easy method can reduce numbn…

This study aims to develop an artificial intelligence system that helps doctors choose the best treatment for each person with esophageal cancer. Researchers will collect data from 7,000 patients, including medical images and tissue samples, to train the AI. The goal is to predic…